Caseinolytic protease B (ClpB) produced by the gut enterobacteria displays anorexigenic effects possibly due to its molecular mimicry with α-melanocyte-stimulating hormone (α-MSH), an anorexigenic neuropeptide. ClpB is known to induce α-MSH cross-reactive antibodies previously associated with eating disorders. In the present study we analyzed whether long-term changes of serum ClpB, anti-ClpB antibodies and fecal clpB gene content can be associated with disease progression in anorexia nervosa (AN). For this purpose, female adolescents diagnosed with the restrictive type of AN according to DSM-5 were studied at hospital admission, discharge, and at a 1-year follow up visit, while age-matched healthy female participants served as a control group. We found that ClpB protein was detected at variable levels in sera of all study participants without significant group differences. However, anti-ClpB IgG were low in adolescents with AN at the acute phase of disease and were characterized by increased affinity. Long-term individual dynamics of serum ClpB revealed that its increase after hospital discharge was associated with disease relapse. In healthy adolescents, serum ClpB correlated negatively with BMI-SDS. Fecal clpB DNA levels were low in patients at hospital admission and discharge correlating positively with the abundance of Enterobacteriaceae in gut microbiota. Thus, in healthy adolescents enterobacterial ClpB appears as a physiological microbiota-derived factor associated with lower body weight within the normal range. Low levels of anti-ClpB IgG in adolescents with AN may cause insufficient immune control of ClpB, possibly promoting ClpB anorexigenic effects which can be relevant to the pathophysiology of AN.
Before the absorption in the intestine, glucose encounters gut bacteria, which may serve as a barrier against hyperglycemia by metabolizing glucose. In the present study, we compared the capacity of enterobacterial strains to lower glucose levels in an in vitro model of nutrient-induced bacterial growth. Two probiotic strains, Hafnia alvei HA4597 (H. alvei) and Escherichia coli (E. coli) Nissle 1917, as well as E. coli K12, were studied. To mimic bacterial growth in the gut, a planktonic culture was supplemented twice daily by the Luria Bertani milieu with or without 0.5% glucose. Repeated nutrient provision resulted in the incremental growth of bacteria. However, in the presence of glucose, the maximal growth of both strains of E. coli but not of H. alvei was inhibited. When glucose was added to the culture medium, a continuous decrease in its concentration was observed during each feeding phase. At its highest density, H. alvei displayed more efficient glucose consumption accompanied by a more pronounced downregulation of glucose transporters’ expression than E. coli K12. Thus, the study reveals that the probiotic strain H. alvei HA4597 is more resilient to maintain its growth than E. coli in the presence of 0.5% glucose accompanied by more efficient glucose consumption. This experimental approach offers a new strategy for the identification of probiotics with increased glucose metabolizing capacities potentially useful for the prevention and co-treatment of type 2 diabetes.